Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
steroids for topical use, acetal derivatives	3135	638-94-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: desonide budesonide acetonide prednacinolone	A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES. Molecular weight: 416.51 Formula: C24H32O6 CLOGP: 2.37 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 93.06 ALOGS: -3.85 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

desonide
budesonide acetonide
prednacinolone

A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES.

Molecular weight: 416.51
Formula: C24H32O6
CLOGP: 2.37
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 93.06
ALOGS: -3.85
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.029		Moderate	0.73
caco2-efflux	Caco-2 efflux ratio (BA/AB)	3.963		Moderate	0.73
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	43.652	10^-6 cm/s	Moderate	0.73
dh-clint	Dog hepatocyte intrinsic clearance	8.974	uL/min/10^6 cells	Moderate	0.73
dppb	Dog plasma protein binding (% unbound)	28.620	%	Moderate	0.73
fcs-ppb	Fetal calf serum protein binding (% unbound)	37.980	%	Moderate	0.73
herg	hERG pIC50	4.305	pIC50	Moderate	0.73
hh-clint	Human hepatocyte intrinsic clearance	6.982	uL/min/10^6 cells	Moderate	0.73
hlm-clint	Human liver microsomal intrinsic clearance	36.224	uL/min/mg protein	Moderate	0.73
hppb	Human plasma protein binding (% unbound)	23.070	%	Moderate	0.73
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK	18
kinase-selectivity-class	GRK2,MAP2K6	2
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	3.707		Moderate	0.73
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	9.247		Moderate	0.73
mh-clint	Mouse hepatocyte intrinsic clearance	28.054		Moderate	0.73
mppb	Mouse plasma protein binding (% unbound)	25.830		Moderate	0.73
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	17.378		Moderate	0.73
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.67
pppb	Pig plasma protein binding (% unbound)	35.620	%	Moderate	0.73
rat-kpuu-brain	Rat brain Kpuu	0.029	%	Moderate	0.73
rh-clint	Rat hepatocyte intrinsic clearance	39.084	uL/min/10^6 cells	Moderate	0.73
rh-fuinc	Rat hepatocyte fraction unbound in incubation	76.480	%	Moderate	0.73
rppb	Rat plasma protein binding (% unbound)	18.290	%	Moderate	0.73
solubility-dd	Solubility at pH 7.4 in DMSO	662.217	uM	Moderate	0.73

Approvals:

Date	Agency	Company	Orphan
Jan. 4, 1972	FDA	PERRIGO NEW YORK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	1445.90	23.17	399	9240	37571	90581237
Chronic sinusitis	507.24	23.17	160	9479	23642	90595166
Paraesthesia oral	412.57	23.17	147	9492	31512	90587296
Vaginal flatulence	403.14	23.17	116	9523	12522	90606286
Female genital tract fistula	388.41	23.17	122	9517	17746	90601062
Radiculopathy	384.20	23.17	122	9517	18383	90600425
Proctitis	381.55	23.17	116	9523	15143	90603665
Vaginal discharge	357.80	23.17	117	9522	19347	90599461
Procedural pain	342.53	23.17	130	9509	33230	90585578
Drug ineffective	337.59	23.17	555	9084	1383743	89235065
Oral candidiasis	289.32	23.17	117	9522	35338	90583470
Dermatitis atopic	272.02	23.17	100	9539	23372	90595436
Haematochezia	242.73	23.17	128	9511	70785	90548023
Frequent bowel movements	242.12	23.17	119	9520	56816	90561992
Colitis ulcerative	241.59	23.17	121	9518	60145	90558663
Rectal haemorrhage	232.33	23.17	131	9508	82613	90536195
Therapeutic product effect incomplete	231.94	23.17	180	9459	193716	90425092
Colitis	224.59	23.17	121	9518	69821	90548987
Erythema	213.60	23.17	184	9455	229062	90389746
Dyspepsia	145.00	23.17	139	9500	198021	90420787
Weight decreased	117.00	23.17	171	9468	379739	90239069
Constipation	97.74	23.17	134	9505	280261	90338547
Dry skin	90.61	23.17	75	9564	87998	90530810
Psoriasis	84.83	23.17	91	9548	147663	90471145
Abdominal pain	75.76	23.17	144	9495	395577	90223231
Eczema	73.90	23.17	54	9585	52816	90565992
Anaemia	70.76	23.17	131	9508	352671	90266137
Skin exfoliation	70.18	23.17	58	9581	67855	90550953
Malaise	62.51	23.17	169	9470	585817	90032991
Infusion related reaction	60.10	23.17	135	9504	416645	90202163
Pyrexia	55.56	23.17	175	9464	660310	89958498
Anhidrosis	51.96	23.17	10	9629	182	90618626
Nausea	50.53	23.17	242	9397	1110074	89508734
Pain	40.17	23.17	210	9429	996131	89622677
Pruritus	38.77	23.17	136	9503	541389	90077419
Cutaneous T-cell lymphoma	34.90	23.17	11	9628	1609	90617199
Joint swelling	32.40	23.17	7	9632	503293	90115515
Headache	32.10	23.17	178	9461	862568	89756240
Off label use	31.30	23.17	212	9427	1102040	89516768
Skin plaque	31.23	23.17	17	9622	9958	90608850
Skin fissures	30.76	23.17	22	9617	20787	90598021
Skin burning sensation	29.60	23.17	21	9618	19590	90599218
Systemic lupus erythematosus	27.90	23.17	3	9636	361893	90256915
Iridoschisis	26.58	23.17	4	9635	14	90618794
Sleep disorder due to a general medical condition	26.41	23.17	28	9611	44710	90574098
Hepatic enzyme increased	25.39	23.17	4	9635	360732	90258076
Synovitis	24.75	23.17	3	9636	329749	90289059
Glossodynia	23.97	23.17	3	9636	321776	90297032
Contraindicated product administered	23.81	23.17	3	9636	320136	90298672
Papule	23.30	23.17	13	9626	7989	90610819

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis atopic	168.36	22.10	55	3286	12349	42605645
Psoriasis	115.27	22.10	62	3279	48542	42569452
Skin exfoliation	76.68	22.10	45	3296	41508	42576486
Dry skin	70.40	22.10	45	3296	48293	42569701
Pruritus	58.82	22.10	73	3268	188698	42429296
Drug ineffective	38.50	22.10	122	3219	630075	41987919
Rash	36.41	22.10	72	3269	276882	42341112
Eczema	35.91	22.10	26	3315	34060	42583934
Sleep disorder due to a general medical condition	35.07	22.10	20	3321	17433	42600561
Anhidrosis	34.97	22.10	7	3334	216	42617778
Madarosis	29.26	22.10	7	3334	499	42617495
Product dose omission issue	29.06	22.10	47	3294	154318	42463676
Ocular hyperaemia	28.64	22.10	17	3324	15946	42602048
Skin burning sensation	27.88	22.10	13	3328	7474	42610520
Melanocytic naevus	27.78	22.10	10	3331	2982	42615012
Eye pruritus	25.43	22.10	14	3327	11398	42606596
Hepatic lesion	23.83	22.10	10	3331	4484	42613510
Conjunctivitis	23.79	22.10	14	3327	12925	42605069
Erythema	23.05	22.10	35	3306	108758	42509236
Cerebral artery thrombosis	22.99	22.10	7	3334	1242	42616752

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	529.19	21.09	158	10477	21501	110557163
Chronic sinusitis	506.32	21.09	158	10477	24926	110553738
Vaginal flatulence	414.60	21.09	115	10520	12029	110566635
Paraesthesia oral	414.26	21.09	146	10489	33525	110545139
Female genital tract fistula	405.55	21.09	121	10514	16398	110562266
Radiculopathy	382.58	21.09	120	10515	19216	110559448
Proctitis	376.87	21.09	115	10520	16812	110561852
Vaginal discharge	374.70	21.09	116	10519	17792	110560872
Procedural pain	343.45	21.09	129	10506	35436	110543228
Dermatitis atopic	303.60	21.09	108	10527	25433	110553231
Oral candidiasis	277.62	21.09	118	10517	44642	110534022
Frequent bowel movements	227.92	21.09	119	10516	71271	110507393
Colitis ulcerative	227.32	21.09	122	10513	77241	110501423
Rectal haemorrhage	209.46	21.09	135	10500	119698	110458966
Therapeutic product effect incomplete	205.99	21.09	171	10464	223634	110355030
Erythema	204.83	21.09	191	10444	291256	110287408
Haematochezia	201.54	21.09	130	10505	115394	110463270
Colitis	198.11	21.09	123	10512	102200	110476464
Dyspepsia	157.34	21.09	137	10498	190828	110387836
Weight decreased	118.17	21.09	182	10453	467875	110110789
Dry skin	117.46	21.09	91	10544	107562	110471102
Psoriasis	110.34	21.09	98	10537	139895	110438769
Skin exfoliation	88.91	21.09	71	10564	87580	110491084
Anhidrosis	86.18	21.09	17	10618	393	110578271
Constipation	83.06	21.09	134	10501	357652	110221012
Eczema	80.76	21.09	62	10573	72231	110506433
Abdominal pain	78.17	21.09	160	10475	512829	110065835
Infusion related reaction	76.81	21.09	134	10501	381028	110197636
Pain	64.82	21.09	220	10415	954735	109623929
Malaise	64.57	21.09	175	10460	671644	109907020
Pyrexia	62.76	21.09	209	10426	898056	109680608
Drug ineffective	59.32	21.09	295	10340	1520245	109058419
Pruritus	56.34	21.09	152	10483	581408	109997256
Madarosis	50.20	21.09	17	10618	3446	110575218
Headache	48.54	21.09	190	10445	882187	109696477
Anaemia	44.20	21.09	134	10501	546952	110031712
Sleep disorder due to a general medical condition	44.05	21.09	38	10597	52074	110526590
Nausea	42.66	21.09	232	10403	1235458	109343206
Skin burning sensation	41.56	21.09	26	10609	21799	110556865
Cutaneous T-cell lymphoma	35.27	21.09	13	10622	3371	110575293
Incorrect dose administered	34.38	21.09	46	10589	103595	110475069
Pain of skin	33.53	21.09	22	10613	20007	110558657
Eye pruritus	32.04	21.09	26	10609	32749	110545915
Eye irritation	31.57	21.09	26	10609	33426	110545238
Off label use	30.59	21.09	247	10388	1499938	109078726
Skin fissures	29.56	21.09	22	10613	24436	110554228
Rash	29.48	21.09	156	10479	820808	109757856
Dry eye	28.77	21.09	31	10604	55762	110522902
Iridoschisis	26.98	21.09	4	10631	14	110578650
Eyelid irritation	26.50	21.09	8	10627	1123	110577541
Product dose omission issue	26.10	21.09	79	10556	321703	110256961
Ocular hyperaemia	26.04	21.09	25	10610	39261	110539403
Injection site pain	25.24	21.09	54	10581	177868	110400796
Therapeutic product effect delayed	25.08	21.09	11	10624	4468	110574196
Drug interaction	24.09	21.09	9	10626	500174	110078490
Acute kidney injury	23.76	21.09	16	10619	635414	109943250
Eye swelling	21.85	21.09	21	10614	33027	110545637
Conjunctivitis	21.45	21.09	21	10614	33771	110544893
Joint swelling	21.27	21.09	8	10627	442837	110135827

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D07AB08	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, moderately potent (group II)
ATC	D07BB02	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS Corticosteroids, moderately potent, combinations with antiseptics
ATC	S01BA11	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Corticosteroids, plain
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D000893	Anti-Inflammatory Agents
CHEBI has role	CHEBI:35472	anti-inflammatory drug

Related Drugs by ATC class:

D07AB Corticosteroids, moderately potent (group II) 12 drugs

alclometasone dipropionate clobetasone butyrate clocortolone pivalate dexamethasone flumetasone fluocortin butyl fluorometholone fluperolone fluprednidene hydrocortisone butyrate hydrocortisone probutate triamcinolone

D07BB Corticosteroids, moderately potent, combinations with antiseptics 3 drugs

flumetasone hydrocortisone butyrate triamcinolone

S01BA Corticosteroids, plain 15 drugs

alclometasone dipropionate betamethasone clobetasol propionate clobetasone butyrate dexamethasone difluprednate fluocinolone acetonide fluorometholone formocortal hydrocortisone loteprednol etabonate medrysone show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Otitis externa	indication	3135009
Atopic dermatitis	indication	24079001	DOID:3310
Crohn's disease	indication	34000006
Contact dermatitis	indication	40275004	DOID:2773
Seborrheic dermatitis	indication	50563003	DOID:8741
Lichen simplex chronicus	indication	53891004
Allergic rhinitis	indication	61582004
Granuloma annulare	indication	65508009	DOID:3777
Pruritus ani	indication	90446007
Asthma	indication	195967001	DOID:2841
Discoid lupus erythematosus	indication	200938002
Plaque psoriasis	indication	200965009
Scalp psoriasis	indication	238608008
Pruritus of genital organs	indication	267802000
Eruption of skin	indication	271807003	DOID:0050486
Primary cutaneous T-cell lymphoma	indication	400122007
Asthma management	indication	406162001
Crohn's disease in remission	indication	426549001
Allergic Rhinitis Prevention	indication
Chronic Non-Allergic Rhinitis	indication
Severe chronic obstructive pulmonary disease	off-label use	313299006
Otitis Externa Eczema	off-label use
Otitis Externa Seborrhea	off-label use
Infection by Strongyloides	contraindication	1214006	DOID:10955
Mycosis	contraindication	3218000	DOID:1564
Ocular hypertension	contraindication	4210003	DOID:9282
Gastritis	contraindication	4556007	DOID:4029
Inactive tuberculosis	contraindication	11999007
Epistaxis	contraindication	12441001
Peptic ulcer	contraindication	13200003	DOID:750
Hypercholesterolemia	contraindication	13644009
Measles	contraindication	14189004	DOID:8622
Disease caused by parasite	contraindication	17322007
Cirrhosis of liver	contraindication	19943007	DOID:5082
Arginase deficiency	contraindication	23501004	DOID:9278
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Viral disease	contraindication	34014006	DOID:934
Immunosuppression	contraindication	38013005
Hypertensive disorder	contraindication	38341003	DOID:10763
Infectious disease	contraindication	40733004
Hypothyroidism	contraindication	40930008	DOID:1459
Hypokalemia	contraindication	43339004
Hypercortisolism	contraindication	47270006
Chronic heart failure	contraindication	48447003
Cerebral malaria	contraindication	53622003	DOID:14069
Tuberculosis	contraindication	56717001
Perforation of tympanic membrane	contraindication	60442001
Congenital hyperammonemia, type I	contraindication	62522004
Osteoporosis	contraindication	64859006	DOID:11476
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Perforation of nasal septum	contraindication	80142000
Hyperglycemia	contraindication	80394007	DOID:4195
Ornithine Carbamyltransferase Deficiency	contraindication	80908008	DOID:9271
Open-angle glaucoma	contraindication	84494001	DOID:1067
Bacterial infectious disease	contraindication	87628006
Muscle atrophy	contraindication	88092000	DOID:767
Herpes simplex	contraindication	88594005	DOID:8566
Operation on nose	contraindication	88733004
Bilateral cataracts	contraindication	95722004
Seizure disorder	contraindication	128613002
Disorder of muscle	contraindication	129565002	DOID:423
Pulmonary tuberculosis	contraindication	154283005	DOID:2957
Ophthalmic herpes simplex	contraindication	186542001
Anastomosis of intestine	contraindication	235407009
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Edema	contraindication	267038008
Pathological fracture	contraindication	268029009
Diverticulitis of gastrointestinal tract	contraindication	271366000
Cerebral trauma	contraindication	275382005
Varicella-zoster virus infection	contraindication	309465005
Osteopenia	contraindication	312894000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Avascular necrosis of bone	contraindication	397758007	DOID:10159
Citrullinemia	contraindication	398680004	DOID:9273
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006
Traumatic rupture of tendon	contraindication	415749005
Exposure to varicella	contraindication	444453009
Nasal Candidiasis	contraindication
Untreated Fungal Infection	contraindication
Uncontrolled Bacterial Infections	contraindication
Nasal Septal Ulcers	contraindication
Nasal Trauma	contraindication
Arginosuccinate Lyase Deficiency	contraindication
Oropharyngeal Candidiasis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.78	acidic
pKa2	12.78	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.05%	VERDESO	GENUS	N021978	Sept. 19, 2006	DISCN	AEROSOL, FOAM	TOPICAL	8460641	Aug. 13, 2027	TREATMENT OF ATOPIC DERMATITIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
4018267	VUID
N0000146597	NUI
D03696	KEGG_DRUG
4018267	VANDF
C0011705	UMLSCUI
CHEBI:204734	CHEBI
CHEMBL1201109	ChEMBL_ID
D003898	MESH_DESCRIPTOR_UI
DB01260	DRUGBANK_ID
5311066	PUBCHEM_CID
7066	IUPHAR_LIGAND_ID
2889	INN_ID
J280872D1O	UNII
3254	RXNORM
1093	MMSL
4550	MMSL
002199	NDDF
412363005	SNOMEDCT_US
52215008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1517	LOTION	0.50 mg	TOPICAL	ANDA	17 sections
LoKara	HUMAN PRESCRIPTION DRUG LABEL	1	0462-0392	LOTION	0.50 mg	TOPICAL	ANDA	18 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0803	LOTION	0.50 mg	TOPICAL	ANDA	19 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0804	CREAM	0.50 mg	TOPICAL	NDA authorized generic	19 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0661	CREAM	0.50 mg	TOPICAL	ANDA	18 sections
DESONATE	HUMAN PRESCRIPTION DRUG LABEL	1	10922-828	GEL	0.50 mg	TOPICAL	NDA	24 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-729	CREAM	0.50 mg	TOPICAL	ANDA	21 sections
DESONIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-944	CREAM	0.50 mg	TOPICAL	ANDA	21 sections
Desonide Ointment, 0.05%	HUMAN PRESCRIPTION DRUG LABEL	1	21922-004	OINTMENT	0.50 mg	TOPICAL	ANDA	18 sections
DESONIDE	HUMAN PRESCRIPTION DRUG LABEL	1	24470-920	GEL	0.50 mg	TOPICAL	ANDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	42254-142	CREAM	0.50 mg	TOPICAL	NDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	45802-423	OINTMENT	0.50 mg	TOPICAL	NDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	46708-485	OINTMENT	0.50 mg	TOPICAL	ANDA	12 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	46708-550	LOTION	0.50 mg	TOPICAL	ANDA	10 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	46708-632	CREAM	0.50 mg	TOPICAL	ANDA	11 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	50436-3300	CREAM	0.50 mg	TOPICAL	ANDA	18 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1280	CREAM	0.50 mg	TOPICAL	ANDA	21 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1281	OINTMENT	0.50 mg	TOPICAL	ANDA	21 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4079	LOTION	0.50 mg	TOPICAL	ANDA	21 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	52565-038	OINTMENT	0.50 mg	TOPICAL	ANDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3284	CREAM	0.50 mg	TOPICAL	NDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4453	OINTMENT	0.50 mg	TOPICAL	NDA	20 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5050	LOTION	0.50 mg	TOPICAL	ANDA	19 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	62332-485	OINTMENT	0.50 mg	TOPICAL	ANDA	12 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	62332-550	LOTION	0.50 mg	TOPICAL	ANDA	10 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	62332-632	CREAM	0.50 mg	TOPICAL	ANDA	11 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	63187-747	CREAM	0.50 mg	TOPICAL	NDA authorized generic	19 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2506	CREAM	0.50 mg	TOPICAL	ANDA	17 sections
Desonide	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2507	CREAM	0.50 mg	TOPICAL	ANDA	17 sections
Desonide Ointment, 0.05%	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8481	OINTMENT	0.50 mg	TOPICAL	ANDA	18 sections

Ask DrugCentral

desonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: